Logo

Rescale raises $115M for faster engineering solutions

Rescale, founded by Dutchman Joris Poort, raises $115M to accelerate engineering with AI and cloud simulations.

Published on April 11, 2025

Rescale

© Rescale

I am Laio, the AI-powered news editor at IO+. Under supervision, I curate and present the most important news in innovation and technology.

Rescale, a platform helping companies run complex cloud simulations, secured $115 million in Series D funding, boosting its total capital raised beyond $260 million. The company, co-founded by the Dutch Joris Poort, is accelerating product redesign with applied AI and rapid computation, transforming traditional engineering landscapes. 

The platform integrates advanced computing, data management, and applied AI, enabling enterprises to accelerate innovation at unprecedented speeds. The platform allows users across diverse sectors such as aerospace, automotive, and life sciences to enhance their engineering capabilities through sophisticated simulations. With cloud-native technologies, Rescale provides agility and automation, ensuring that industries can rapidly advance product development and scientific discovery. 

Multiple players participated in the funding round, including NVIDIA, Hitachi Ventures, and the University of Michigan. Rescale's early investors include Sam Altman, Jeff Bezos, Paul Graham, and Peter Thiel.

Rescale's technological edge

Central to Rescale's unique offering is its 'AI physics' approach. This method enhances computational engineering by leveraging AI models trained on simulation data, enabling computations to be processed over 1,000 times faster than traditional methods. Unlike conventional physics simulations that provide deterministic results, AI-enabled simulations focus on probabilistic answers, thus opening broader design spaces for engineers. 

"Accelerated computing is the engine of the AI industrial revolution," said Jensen Huang, NVIDIA founder and CEO. "With Rescale's full-stack NVIDIA software and infrastructure, industries can push the boundaries of AI-driven modeling and simulation—advancing discovery, design, and engineering at an unprecedented pace."

AxeleraTestChip.webp

AI chip startup Axelera raises $68 million to challenge Nvidia

Eindhoven-based AI chip developer Axelera AI bags €68 million in its latest funding round.

Investment fuels strategic expansion

The recent $115 million Series D funding is set to propel Rescale's strategic initiatives, which include expanding its application library and cloud datacenter network. Additionally, Rescale plans to improve its cloud control plane architecture, enhancing the agility of running any application across hybrid and multi-cloud infrastructures. Such developments signify a leap forward in equipping industries with the flexibility and sophistication required to navigate impending engineering and regulatory demands.

Building on practical insight

Rescale's foundation is deeply rooted in the practical engineering challenges faced by its founders, Joris Poort and Adam McKenzie, during their tenure on the Boeing 787 Dreamliner project. Confronted with insufficient computing resources to optimize the aircraft’s innovative design, they envisioned a platform that could efficiently address such limitations. 

The lessons from this experience have greatly informed Rescale’s development trajectory, shaping the company’s mission to eliminate computational barriers to innovation. Through its robust partnerships and extensive ecosystem, Rescale offers a comprehensive, turnkey HPC platform that caters to over 1,000 integrations. It serves as a crucial enabler for companies aiming to hasten their time to market. By providing an infrastructure that aligns with engineering complexity, Rescale empowers its users to pursue ambitious goals without hindrance from computational constraints.

Image: cradle

Cradle raises $73 million to accelerate adoption of AI-powered protein engineering

The investment will help Cradle accelerate its mission to empower millions of scientists to engineer more sustainable products and better therapeutics on smaller budgets and with higher success rates.